



FIG. 1.

2/17





3/17




FIG. 4.




FIG. 5.




FIG. 6.


U

12

j-4

Title: SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR IMPROVING TREATMENT OF

MEDICAL PATIENTS Inventor(s): Richard Burgess Atty Dkt No.: 34702/214150



<u>FIG. 7.</u>

$\ \, \text{Title: SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR IMPROVING TREATMENT OF } \, \,$

MEDICAL PATIENTS Inventor(s): Richard Burgess Atty Dkt No.: 34702/214150




FIG. 8.

8/17




FIG. 9.

Atty Dkt No.: 34702/214150




FIG. 10.

10/17




FIG. 11.

Title: SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR IMPROVING TREATMENT OF

MEDICAL PATIENTS Inventor(s): Richard Burgess Atty Dkt No.: 34702/214150




FIG. 12.




FIG. 13.




FIG. 14.

Title: SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR IMPROVING TREATMENT OF MEDICAL PATIENTS Inventor(s): Richard Burgess Atty Dkt No.: 34702/214150

170	e
Physician - Microsoft Internet Explorer	ि ् े ा 5
Edit View Pavorites Tools Help Links @Finance @CNN @MSNBC @USAToday @CNBC: @MSN @CEO @MapQuest @Radio	→ ₹
(-) 2 2 3 @ Search (in Favorites) Media () 2 - 3 7 - 1 12 Address ()	
ew Physician Request	
questing Physician Profile	7
ne Dr. Ima Neww tace Jersey Shores Medacal	
User Since 28-Oct-2001	
fessional Background	
essional Datreyound	
Accept to my Request Queue Reject Request (Return to Index)	
	My Computer

FIG. 15.

File Edit View Payorites	Took Help Links	Finance BONN BIMSNBC B	Q Address (δ)	lung appearance of the second	**************************************	. ⊗
Wandt wordt would				, , , ,	*# 11 1 1 16	A
Initial Treat						*****
	XXXXXXXXX (Collection Date: dd-mmr				
Gender: Mair Age	29 Height /2 m	Weight 165 ds BMI 22	6			
Suspected Date of Sere		1				
CD4 count at time of di		", Next most recent CD4 (oune 550 on 1 Jul 20	101		1
		i, Next must recout viral le				
Churcal Symptoms (c)						
1		sian on request for a relative to	circal synptoms			
Co Morbidates Hep at						
ADL Issues Parentes		and on request form relative to	(o morotomer			1 :
		cian on recruest form relative to	ALIL insue«			1
Patient Preferences						- 1
Comments m	post by secureting sity's	cran on request form relative to	descal jung to as			
Assessment of Patient				_		
Comments to	put by rect estructibles.	atta, un request four relative to	patient's audity to whe	re to therapy		1.
L						1
-Pa						1
Resistance M. Febbre NNRT	utations 1 <u>Protease</u>	Polymorphisms Rm Clene Pro ease	Resistanc (accur chu	eo <u>g • 5 (Genotype)</u>		
Ng.4 3 9 × 17 84	71 I 77 V		Mytations a	t 35~ are nesociated	with 2D9781 C dual re-	sist made
34	77 V			_		1
	•	- 102		10)2	- 1
<u> </u>						
- Suggested Drug Res			n you reply	nutual course of treatmen	t Issues to consider in cho	oosing a
regimen include potentia	gmens - Check if you it show genotypic evide al tometry, patient comp		nt your reply e We recommend an ents, drug absorption ar	mmal course of treatmented drug metabolism. Co	t Issues to consider in cho	oosing a
regimen include potential nucleosides and a prote	gmens - Check if you it show genotypic cyide il toxicity, patient comp ase inhibitor	a want the following printed of ence of significant drug resistant chance with past medical treatm	ents, drug absorption ar	_		F
regimen include potential nucleosides and a prote	gmens - Check if you it show genotypic cyide il toxicity, patient comp ase inhibitor		ents, drug absorption ar	_		F
f "This isolate does no regimen include potentia nucleosides and a prote "This isolate shows i include potential toxicity a protease inhibitor"	gumens - Check if you it show genotypic evided il tonicity, patient comp ase inhibitor " genotypic evidence of s , patient compliance w	a want the following printed is ence of significant drug resistant chance with past medical tream significant drug resistance. We the past medical treatments, drug	ents, drug absorption ar recommend an initial co- ig absorption and drug r	urse of treatment Issue metabohsm. Consider a	s to consider in choosing a regimen containing nucleos	F
First Regimen (chec	gamens - Check if you is show genotypic could it tomely, patient comp are milities' genotypic condence of s genotypic condence w ick all that apply) Nucleosides	a want the following printed of ence of significant drug resistant chance with past me deal treatment with past me deal treatment drug resistance. We see that past me deal treatments, drug resistance. Note that past me deal treatments, drug resistance of the past me deal treatments and the second resistance of the secon	recommend an untial cog absorption and drug :	metabolism. Consider a	os to consider in choosing a regimen containing nucleosi Other Hydroxyurea	F
F "The stolate does no regmen include potential nucleosides and a prote "The stolate hows; include potential toxicity a protease inhibitor" First Regimen (chec TDDV Tdd	gamens - Check if you to show genotype wide it to some, patient comp are inhibitor "genotype evidence of s, patient compliance w check all that apply) Nucleosides	a want the following printed a since of significant drug resistant chance with past medical treatments, drug in the past medical treatments and in the past medical treatments of the past medical treatment of the past medical	ents, drug absorption ar recommend an initial co- ig absorption and drug r	urse of treatment Issue metabolism. Consider a	s to consider in choosing a regimen containing nucleos	F
f "This isolate does no regimen include potential nucleosides and a protein a protein a protein a protein a protein michae potential boxaci, a protein michae potential boxaci, a protein michae protei	gamens - Check if you to show genotype wide it to some, patient comp are inhibitor "genotype evidence of s, patient compliance w check all that apply) Nucleosides	want the following printed a conce of ngindicant drug resistant shance with past medical treatments are not shadown to the past medical treatments, druggificant drug resistance. We in the past medical treatments, druggificant drug resistance. We NNRITE data To Delawardine STC Fefaviera.	ents, drug absorption at recommend an minal cog absorption and drug reference of the first state of the firs	nerse of treatment Issue metabohsm. Consider a Gase Inhibitors F Ritonavir	os to consider in choosing a regimen containing nucleosi Other Hydroxyurea	r
F "The stolate does no regmen include potential mulcleoardes and a prote include potential toxacia a protease ministro con a p	gamens - Check if you to show genotype wide it to some, patient comp are inhibitor "genotype evidence of s, patient compliance w check all that apply) Nucleosides	a want the following printed a since of significant drug resistant chance with past medical treatments, drug in the past medical treatments and in the past medical treatments of the past medical treatment of the past medical	ents, drug absorption at recommend an minal cog absorption and drug reference of the first state of the firs	nerse of treatment Issue metabohsm. Consider a Gase Inhibitors F Ritonavir	os to consider in choosing a regimen containing nucleosi Other Hydroxyurea	r
F "The stolate does an regimen include potential mucleosades and a prote T The stolate shows; include potential tonicity a protease inhibitor." Erist Ragimen (ches T ZDV ddl r dde r f	gamens - Check if you to show genotype wide it to some, patient comp are inhibitor "genotype evidence of s, patient compliance w check all that apply) Nucleosides	a want the following printed a since of significant drug resistant chance with past medical treatments, drug in the past medical treatments and in the past medical treatments of the past medical treatment of the past medical	ents, drug absorption at recommend an minal cog absorption and drug reference of the first state of the firs	nerse of treatment Issue metabohsm. Consider a Gase Inhibitors F Ritonavir	Other Hydroxyurea Foscamet	r
F "The stolate does an regimen include potential mucleosades and a prote T The stolate shows; include potential tonicity a protease inhibitor." Erist Ragimen (ches T ZDV ddl r dde r f	gamens - Check if you to show genotype wide it to some, patient comp are inhibitor "genotype evidence of s, patient compliance w check all that apply) Nucleosides	a want the following printed a since of significant drug resistant chance with past medical treatments, drug in the past medical treatments and in the past medical treatments of the past medical treatment of the past medical	ents, drug absorption at recommend an minal cog absorption and drug reference of the first state of the firs	nerse of treatment Issue metabohsm. Consider a Gase Inhibitors F Ritonavir	Sto consider in choosing a regimen containing nucleosing a regimen Containing nucleosing a Cherry Hydrogymen Foscamet	r
F "The stolate does no regmen mode optenin nucleosades and a prote f"The soular shows; sinclude potenhal tonach a protease mibitor." Fast Regimen (chesting of the soular shows; fold fold fold fold fold fold fold fold	gmens - Check if you to those genetypic evidence are inhibitor." genotypic evidence of senotypic evidence of senotypic evidence we can the senotypic evidence of senotypic evidence we can the senotypic evidence of senotyp	a want the following printed a since of significant drug resistant share with past medical treatments, drug resistance. We may a suppose the same of t	ents, drug absorption as recommend an unital cog absorption and drug to gasorption and drug to the commendation of the commend	urse of treatment Issue metaboksm. Consider a Labibutors Raconsor Nelfinave	Other Hydroxyurea Foscamet	regimen ides and
F "The stolate does an regimen include potential nucleosades and a prote T The subtle shows include potential tossen; a proteas enhabitor . First Regimen (class T T T T T T T T T T T T T T T T T T	gamens - Check if you to those generally a construction of the compliance with the com	want the following printed a since of significant drug resistant shane with past medical treatments, drug resistance with past medical realments, drug resistance with past medical treatments, drug resistance in the past medical treatments of the past medical treatm	ents, drug absorption as recommend an unital cog absorption and drug i Prot Indinave Saquinave Saquinave Amprenave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Todanave Prot Prot Todanave Prot P	metaboksm. Consider a Labibutors Raconavr Nelfinavr I Reconsve	Other	regimen ides and
F "The stolate does an regmen midde potential muldeosades and a prote f"The stolate shows; include potential tonact; a prote as embibitor." Fast Regimen (chest grade) Gomments Second Regimen (chest grade) Second Regimen (chest grade) Comments	gamens - Check if you t show genetype evide it loosely, patent comp ase mhibitor " genotype evidence of s the all that apply) Nucleosides I Check all that apply)	want the following printed a since of significant drug resistant share with past me dical treatments, drug resistance we in the past me dical treatments, drug resistance we in the past me dical treatments, drug resistance we in the past me dical treatments, drug resistance with the past me dical treatments of the pas	ents, drug absorption at recommend an unital cog abrorption and drug to provide the second of the se	urse of treatment Issue metabolism. Consider a passe Inhibitors Reconsider	Other	regimen ides and
F "The stolate does an regmen midde potential mulleosades and a prote f"The subdite shows include potential tonact, a prote as enhibitor." Forst Regimen (ches dd	gamens - Check if you is show genotypic ends it loosely, palent compare substor genotypic ends g	a want the following printed a since of significant drug resistant charge resistant past medical treatments, drug resistant drug resistance. We in past me dical treatments, drug resistant drug resistance. NNRIIS F Delawrienz F Efavirenz F Efavirenz F Nevrapine F Any NNRTI NNRIIS NNRIIS NNRIIS P Delawrienz P D Delawrienz P D D D D D D D D D D D D D D D D D D	ens, drug absorption at recommend an unital cog abrorption and drug i Frot Findmawr Faquinawr Faquinawr Amprenawr Faquinawr Fa	urse of treatment Issue metabolism. Consider a passe Inhibitors Reconsvr Nelfinavvr Teneral Reconsvr	Other Hydrosyura Foscamet Foscamet Cher Cher Foscamet Cher Cher	regimen ides and
F "The stolate does an regmen midde potential muldeosades and a prote f"The stolate shows; include potential tonact; a prote as embibitor." Fast Regimen (chest grade) Gomments Second Regimen (chest grade) Second Regimen (chest grade) Comments	gamens - Check if you is show genotypic ends it loosely, palent compare substor genotypic ends g	want the following printed a since of significant drug resistant share with past me dical treatments, drug resistance we in the past me dical treatments, drug resistance we in the past me dical treatments, drug resistance we in the past me dical treatments, drug resistance with the past me dical treatments of the pas	ens, drug absorption at recommend an unital cog abrorption and drug i Frot Findmawr Faquinawr Faquinawr Amprenawr Faquinawr Fa	urse of treatment Issue metabolism. Consider a passe Inhibitors Reconsvr Nelfinavvr Teneral Reconsvr	Other	regimen ides and
F "The stolate does an regmen midde potential mulleosades and a prote f"The subdite shows include potential tonact, a prote as enhibitor." Forst Regimen (ches dd	gamens - Check if you is show genotypic ends it loosely, palent compare substor genotypic ends g	want the following printed a since of significant drug resistant share with past me dical treatments, drug resistance we in the past me dical treatments, drug resistance we in the past me dical treatments, drug resistance we in the past me dical treatments, drug resistance with the past me dical treatments of the pas	ens, drug absorption at recommend an unital cog abrorption and drug i Frot Findmawr Faquinawr Faquinawr Amprenawr Faquinawr Fa	urse of treatment Issue metabolism. Consider a passe Inhibitors Reconsvr Nelfinavvr Teneral Reconsvr	Other Hydrosyura Foscamet Foscamet Cher Cher Foscamet Cher Cher	regimen ides and
F "The stolate does an regmen midde potential mulleosades and a prote f"The subdite shows include potential tonact, a prote as enhibitor." Forst Regimen (ches dd	gamens - Check if you is show genotypic ends it loosely, palent compare substor genotypic ends g	want the following printed a since of significant drug resistant share with past me dical treatments, drug resistance we in the past me dical treatments, drug resistance we in the past me dical treatments, drug resistance we in the past me dical treatments, drug resistance with the past me dical treatments of the pas	ens, drug absorption at recommend an unital cog abrorption and drug i Frot Findmawr Faquinawr Faquinawr Amprenawr Faquinawr Fa	urse of treatment Issue metabolism. Consider a passe Inhibitors Reconsvr Nelfinavvr Teneral Reconsvr	Other Hydrosyura Foscamet Foscamet Cher Cher Foscamet Cher Cher	regimen ides and
F The stolate does an ergamen include potential mucleosades and a prote The stolate shows; anclude potential tossen, a proteas enhabitor: Parst Regimen (checker) Parst R	gamens - Check if you as show genotypic evide it country, about compare substor it genotypic evide genotypic evidence of a patient compliance which all that apply) Nucleosides	want the following printed a since of significant drug resistant share with past medical treatments, drug resistance we in the past medical treatments, drug resistance we in the past medical treatments, drug resistance we in the past medical treatments, drug resistance with past medical treatments, drug resistance in Figure 1. Note	Protection of the second of th	ness of treatment Issue metabolism. Consider a pass Inhibitors Rationave Rationave Rationave Richnave Richnave	Sto consider in choosing a regimen containing nucleon Thydroxyurea Foscamet Foscamet Foscamet Foscamet Foscamet Foscamet Foscamet Other	regmen des and
F The stolate does an regimen include potential nucleosades and a prote This soulte shows; and the stolate shows; a proteas enhabitor: First Regimen (checked) First Regimen (checked) For the stolate shows; a proteas enhabitor: First Regimen (checked) Comments Second Regimen (checked) First Regimen (checked) Comments	gmens - Check if you is show genotypic evidence in country and towns are inhibitor. The compliance we genotypic evidence of spentypic evidence of your patient compliance we kall that apply) "Rucleosidax" For the check all that apply) Check all that apply Check all that all that apply Check all that apply Check all that apply Check all that apply	want the following printed a ence of significant drug resistant charge existant particular that is a significant drug resistant with past me due all reatments, drug resistant drug resistant with past me due all reatments, drug resistant drug resistant with past me due all reatments, drug resistant past of the significant drug resistant drug resistant past of the significant drug resistant past of the sign	Pro F Indmawr F Amprenawr F Amprenawr F Amprenawr F Amprenawr F Amprenawr F Tadanawr	nese of treatment Issue metabolism. Consider a Dass Inhibitors Riconavi R	Other Hydrogyura	regmen des and
F "The stolate does an regimen include potential mucleosades and a prote include potential tosach, a proteas enhabitor enhabit	gamens - Check if you as show genotypic evide it country, about compare substor it genotypic evide genotypic evidence of a patient compliance which all that apply) Nucleosides	a want the following printed a ence of significant drug resistant chance with past medical treatments, drug resistant drug res	Protection of the second of th	nese of treatment Issue metabolism. Consider a passe Inhibitors Reconswr Refinavr Refinavr Refinavr Refinavr Refinavr Refinavr	Other Other Flydrosyurea Foscamet	regmen des and
F The stolate does an regimen include potential nucleosades and a prote This solute shows; and the solution of	gmens - Check if you is show genotypic evidence in those years of your compliance we genotypic evidence of senotypic evidence of senotypic evidence of years (years) you have	want the following printed a since of significant drug resistant charge resistant charge resistant are significant drug resistance. We significant drug resistance. In Part of Education of Education of Part of the State of	Protection and an annal cog absorption and drug a Protection and drug a Protection and drug a Protection and an annal and a Protection and an annal and a Protection and an annal and a Protection and a Protectio	nese of treatment Issue metabolism. Consider a Dass Inhibitors Riconavi R	Other Hydroxyurea Faccarnet Foccarnet Foccarn	regmen des and
F "The stolate does an regimen include potential mucleosades and a prote include potential tosach, a proteas enhabitor enhabit	gmens - Check if you is show genotypic evidence in those years of your compliance we genotypic evidence of senotypic evidence of senotypic evidence of years (years) you have	a want the following printed a ence of significant drug resistant chance with past medical treatments, drug resistant drug res	Protection and an annal cog absorption and drug a Protection and drug a Protection and drug a Protection and an annal and a Protection and an annal and a Protection and an annal and a Protection and a Protectio	nese of treatment Issue metabolism. Consider a Dass Inhibitors Riconavi R	Other Other Flydrosyurea Foscamet	regmen des and
F The stolate does an regimen include potential nucleosades and a prote This solute shows; and the solution of	gmens - Check if you is show genotypic evidence in those years of your compliance we genotypic evidence of senotypic evidence of senotypic evidence of years (years) you have	a want the following printed a ence of significant drug resistant chance with past medical treatments, drug resistant drug res	Protection and an annal cog absorption and drug a Protection and drug a Protection and drug a Protection and an annal and a Protection and an annal and a Protection and an annal and a Protection and a Protectio	nese of treatment Issue metabolism. Consider a Dass Inhibitors Riconavi R	Other Hydroxyurea Faccarnet Foccarnet Foccarn	regmen des and
F The stolate does an regimen include potential nucleosades and a prote This solute shows; and the solution of	gmens - Check if you is show genotypic evidence in those years of your compliance we genotypic evidence of senotypic evidence of senotypic evidence of years (years) you have	a want the following printed a ence of significant drug resistant chance with past medical treatments, drug resistant drug res	Protection and an annal cog absorption and drug a Protection and drug a Protection and drug a Protection and an annal and a Protection and an annal and a Protection and an annal and a Protection and a Protectio	nese of treatment Issue metabolism. Consider a Dass Inhibitors Riconavi R	Consider in choosing a regimen containing nucleon in the program of the program o	regmen des and
F The stolate does an regimen include potential nucleosades and a prote This solute shows; and the solution of	gmens - Check if you is show genotypic evidence in those years of your compliance we genotypic evidence of senotypic evidence of senotypic evidence of years (years) you have	a want the following printed a ence of significant drug resistant chance with past medical treatments, drug resistant drug res	Protection and an annal cog absorption and drug a Protection and drug a Protection and drug a Protection and an annal and a Protection and an annal and a Protection and an annal and a Protection and a Protectio	nese of treatment Issue metabolism. Consider a Dass Inhibitors Riconavi R	Consider in choosing a regimen containing nucleon in the program of the program o	regmen des and
r The stolate does an regimen include potential mucleosades and a prote r This solate shows; and the solate shows; a proteas enhabtor: Figure	gmens - Check if you is show genotypic evidence in those years of your compliance we genotypic evidence of senotypic evidence of senotypic evidence of years (years) you have	a want the following printed a ence of significant drug resistant chance with past medical treatments, drug resistant drug res	Protection and an annal cog absorption and drug a Protection and drug a Protection and drug a Protection and an annal and a Protection and an annal and a Protection and an annal and a Protection and a Protectio	nese of treatment Issue metabolism. Consider a Dass Inhibitors Riconavi R	Other Other Hydrosyura Foscamet Poscamet Pos	regmen des and

FIG. 16.

Back • 🛊 • 🗿 🗓 🐧 () Search (a) Favorites () 🖟		•] Links @)Financ	s Brini Einger S	USAToday @Welcome to TIME.com	
ques & A. T. Wesam Bi divine A.	M. O. FI. S. S.	. 3 - mis Emai	s Edus Elionir e	novinos) . El serone re merral	i A.
11-					
Viralogic Failure / Salva Specimen No. XXXXXXXXXXXXX Collec					, •
-Pauent Profile Gender Male Age 29 Height "'m Wes	udic 163 th STATE 3	3.4			
CD4 count at time of diagnosis 579					
Mostrecent CD4 tount 525 on 1 + Sep 2001. No Mostrecent viral lead 8400 on 75 Sep + 91. No					
ILAAR I History Current Medications Start Fair Stop Dan Later 12 to 2200					
menske i 2 13/2000 5. parasa - 12 12/2000 HAART Mittury - Freylons Madicanious					
Co Morbuhites Hapetins C. Diabetes (1990 L.) Leg					-
Comme its injust by requesting a system on	request form, relative t.	co woul duber			-
ADL Isames. Fapert eats recular ries of Patient is wo Community input by requesting payorian or		ADI INSUA			1
Pateint Perferences	reque tirm, relative to	charal some was			
Assessment of Patient's Alphry to Adhere to Their		, spent's analyte who	ince to throupy		
Panon Resistance Ropert					
Resistance Moranous P ymorph River (TERNTS Provinces ET Tente 23 To 11		n-water (Pranstance)	aton and SOSVITT dual	and a statement	
102				02	
Suggested Drug Regment - Check if you want to ""The solate does not show genotypic evidence of a regmen include potential toxicity, patient compliance w	he following printed a	a your reply	·····	·	e "
nucleosides and a protease inhibitor. "This isolate shows genetypic evidence of significant include potential toucity, patient compliance with part a protease inhibitor."					
	medica, deaments, aru	g mosorphon and drug	metabolim Consider a	regimen containing nucleosides	
Farst Regimen (check all that apply) Nucleondes F 2DV F 3TC	NNRTIs Delayirdme Efavirent	Prot	Ratonavu	Other Hydroxynra Foscarnet	וַ וּ
t ddc 1 abacawa	r Nevrapine r Any NNRTI	Amprenavir	Nelfinavur	Forcarier	-
''				لف	- 1
Comments					- 1
				لت	
Comments Second Regimen (check all that apply) Nucleosides	MMRTIS	Pro	tense Inhibitors	Other	
Second Regumen (check all that appth) Nucleousides Factor F	Delavirdine Efavirenz Nevirapine	F Industri ! Saquastri ! Amprenava	tense Inhibstors (** Ratonavi (** Nelfinavi (**)		
Second Regumen Check oil that apply) PZDV Nucleowides F 2DV 7 STC 6	Delavirdine "Efavirenz	I Saquinavir	" Nelfinavir	Other Hydroxyures Foscarant Foscarant	
Second Regimen (check all that apply) Second Regimen (check all that apply) Nucleo sides F ZDV Nucleo sides F ZDV 1 44T (14T (14T)	Delavirdine Efavirenz Nevirapine	I Saquinavir	" Nelfinavir	Other Fightopywaa Focusement Focusemen	
Second Regimen (check all that apply) Second Regimen (check all that apply) T ZDV Nacionardes T ZDV T ddT T dd T STC T ddc T abacever T T T T T T T T T	Delawrdms "Efavurenz Newrapms Any NNRTI	I Saquinavir	" Nelfinavir	Other Taydrolywea Forcamet Taydrolywea Taydrolywea	-
Second Regimen (check all that apply) Second Regimen (check all that apply) Figure 1 ATT Add 1 ATT Add 1 ATT Comments Third Regimen (check all that apply) Nucleoradas Nucleoradas 1 ATT 1 ATT 1 ATT 1 ATT 1 ATT	Delawrdme Efavrenz Newrapme Any NNETI SNRTIE Delawrdme Efavrenz Efavrenz	Indinavr Saquasur Saquasur Saquasur Pool Indinavr Pool Indinavr Saquasur Saquas	Case Inhibitors	Other Hydrotyruse Foremet	
Second Regimen (check all that apply) Fizity Fatic Fidd Fabacove Figure Regimen (check all that apply) Third Regimen (check all that apply) Third Regimen (check all that apply) Third Regimen (check all that apply) Fidd Fatic Fidd Fatic Fidd Fatic Fidd Fatic Fidd Fatic Fidd Fatic	Delawrdine Efavrenz Newrapine Any NNRTI	C Amprenava	Case Tabletors	Other Flydrosyrum Focamet Tocamet Tocamet Other	
Second Regimen (check all that apply) TZDY Nucleonation TZDY F4T F dd	Delawrdine Efavrenz Newrapine Any NNRTI NNRTI Delawrdine Efavrent Newrapine	Indinavr Saquasur Saquasur Saquasur Pool Indinavr Pool Indinavr Saquasur Saquas	Case Inhibitors	Other Flydrosprum Fossman	
Second Regimen (check all that apply) Fizity Fatic Fidd Fabacove Figure Regimen (check all that apply) Third Regimen (check all that apply) Third Regimen (check all that apply) Third Regimen (check all that apply) Fidd Fatic Fidd Fatic Fidd Fatic Fidd Fatic Fidd Fatic Fidd Fatic	Delawrdine Efavrenz Newrapine Any NNRTI NNRTI Delawrdine Efavrent Newrapine	Indinavr Saquasur Saquasur Saquasur Pool Indinavr Pool Indinavr Saquasur Saquas	Case Inhibitors	Other Hydrocycures Focasest	
Second Regimen (check all that apply) Fizity Fatic Fidd Fabacove Figure Regimen (check all that apply) Third Regimen (check all that apply) Third Regimen (check all that apply) Third Regimen (check all that apply) Fidd Fatic Fidd Fatic Fidd Fatic Fidd Fatic Fidd Fatic Fidd Fatic	Delawrdine Efavrenz Newrapine Any NNRTI NNRTI Delawrdine Efavrent Newrapine	Indinavr Saquasur Saquasur Saquasur Pool Indinavr Pool Indinavr Saquasur Saquas	Case Inhibitors	Other Flydrosprum Fossman	

FIG. 17.

3	rites Tools Help	A Paragraph		किन्दिक			
\$ Back • • • 0 3]] OSearch [Fav	vortes 🆣 Média (18.31	Jinks Finance	SON SWORE SO	AToday (a) Welcome to	TIME.com
Address 🐔							v \$60
Toxicity 1	Problem R	eply		****			<u> </u>
-Person Profile-	>>>>>>>						
Gender Mair	Age ~ Height 7/ d Serocenversion 1 cb		n+ih> HMI 22	6			
CD4 count at time	n of diagnosis 5/9 i count 32° on 29 Sep		ser vocant CD4 s	naat 550 on 1 Jan ^	001		
Most recent vaul	Land blucon V Set	ones, Next ma	est succest vir d lo	and 1000 um Loran 20	rn.		
HAARI Histor	Y - Current Medici Date Stor Date	u stojns Pro Ses	man ka 'n far ('	monte a françaire			
Zakatabane 12/16/ Sagoraver 17/18							
DAART Histor	ry Previous Medis	arious					
	Hepanus C Diabetes (6)			an w. buddage			
	ent on the largest P			(0 11 11 11 11 11			
1 1	arm manus ps reclarations to	ophen on necht	et tourn re unive *>	Mal nemer			
Patient Preierone	. "Le when p2 redne: _w6 k	bpareism on redise	er form relative to	clena al sympt me			
	ationt's Ability to Adhe		Trait of slove to	pagagaras abaas te ado	ere in their you		
(7)		11, 11, 11, 11, 11, 11, 11, 11, 11, 11,					
1							
Patient Resistan	1.007	I obymospousous	Resist	ance			
Prostance Motor	Dr tonic 1	I olymorpharns Billene Phili	830 [3653	rd on to (senetype)	and with ZZV/ZTG down	cylate	
Brustance Motor	1.007	Bitmac Pasta	830 [3653	rd on to (senetype)		CNAxtarur	
Prostance Motor Nuzz SNAST 222 F	21 T // V	- 102	Marke Marke	rdua to (ornetype) one at 303 me associ	102		choosing a
Provided Meter Number of States of S	Prints 1 71 T 71 T 71 T 72 T 73 T 74 T 75 T 76 T 77	- 102 you want the followidence of signafe compliance with pa	Macus Macus Macus Howing printed or ant drug resistance at medical treatment	a vous reply We recommend an	mbal course of treatment and drug metabolum Con	Issues to consider in sider a regimen contai	choosing a name
Nurse Miles	Regiment - Check it os not show genotype e otertial towarty patent e protease whattor " ower genotype evidence ownerty, patent compliant compliant."	- 102 you want the followidence of signafe compliance with pa	Macus Macus Macus Howing printed or ant drug resistance at medical treatment	a vous reply We recommend an	102	Issues to consider in sider a regimen contai	choosing a mang a regiment cosides and
Nutra FRAH 222 F Suggested Drug F This isolate do regimen include pe nucleousdes and a F This isolate is include potential it a protease inhabito	g Regimens - Check il oss not show genotype e otential toxativy patent e protease substitor or convergency patent e concern genotype evidence concern, patent compliancy (check all that apply)	- 102 you want the followidence of signafe compliance with pa	Nous Cases Nous Cases Llowing pranted or cant drug resistance in the cases of the	one at 222 are described as your reply We recommend an initial co	102 minul course of freatment and drug metabolum Con	Issues to consider in older a regimen contu- to consider in choosis organen containing nucl	eosides and
Num TRAIT 700 F Num TRAIT 700 F Numgested Drug F This relate de regimen include per nucleondes and a F This relate in nucled proteonal re a proteonal re a proteonal re Trait relate in Number of the related proteonal Trait Regimen	Regiment - Check it os not show genotype e otertial towarty patent e protease whattor " ower genotype evidence ownerty, patent compliant compliant."	- 102 you want the followed the summer with part medical with part	Macus Macus Macus Howing printed or ant drug resistance at medical treatment	n vous reply n vous reply We recommend an initial ce p absorption and drug Lindanser Indoneser Indoneser Indoneser Indoneser	102 unhal course of treatment and drug metabolum Consider a remarkabolum Consideration Considerat	Issues to consider in sider a regimen contai	cosides and
Note NAME OF STREET OF STR	g Regimens - Check il oss not show genotype e otential toxativy patent e protease substitor or convergency patent e concern genotype evidence concern, patent compliancy (check all that apply)	- 102 - you want the following	Much Howing pranted or cant drug resistance ist medical treatments resistance We real treatments drug NNRTLs Delayardane	wing to impressed	102 mittal course of reatment indidug metaboham Consucre of treatment. Issues metabolism Consider a r	Issues to consider in choose to consider in choose ogmen containing nucl	cosides and
NUM TRACT 249 F Num TRACT 249 F Numeround Drug F Than stolate do regemen include per nucleonades and a F Thu stolate a protenate rabbits protenate a protenate milutor protenate rabbits protenate milutor prote	Pricas: 21 T 21 T 21 T 22 T 23 T 24 F ginners - Cherk it 25 not show genotypue o control toxocity patent control toxocity patent control toxocity patent cover genotypue evidence xow geno	- 102 - you went the fellow you want to fellow you want to fellow you want to get to the fellow you will past mode	Much. Mich. Mi	wing to contensive in your reply a your reply recommend an untal of absorption a commend an untal of absorption and drug Industry I Sequency I Sequency I Amprenaver	102 unhal course of treatment and drug metabolum Consider a remarkabolum Consideration Considerat	Issues to consider in cider a regimen contact to consider in choosing much containing nucleus of the containing nucleus of the contact of the	cosides and
NUM TRACT 240 F This relate do regemen include pe mucleoudes and a F This relate do regemen include pe mucleoudes and a fr This relate the mucleoude potential is a protesse mission of the period	Pricas: 21 T 21 T 21 T 22 T 23 T 24 F ginners - Cherk it 25 not show genotypue o control toxocity patent control toxocity patent control toxocity patent cover genotypue evidence xow geno	- 102 - you went the fellow you want to fellow you want to fellow you want to get to the fellow you will past mode	Millowing pranted of and day resistance used to be a selected freshment of all treatments drug resistance where all treatments drug resistance. We real treatments drug resistance for the selected freshments and treatments drug resistance for the selected freshment of the select	wing to contensive in your reply a your reply recommend an untal of absorption a commend an untal of absorption and drug Industry I Sequency I Sequency I Amprenaver	mind course of treatment and drug metabolum Computer of treatment Listues metabolum Consider a results. Bulbutters	Issues to consider an order a regimen contact to consider in choosing much containing nucleus and the containing nucleus and the contact and t	cosides and
Num FRAIT 1932 F Num FRAIT Page and Drag F This include do regimen include per mich codes and a F This include and a protesse tubbic For Regimen Frait Governments	Prints 1 711 711 W Regiment - Check it sees not show genetype e ctembal tonority palente a proteam alleithe evidence over genetype evidence, palent complaint (Check all that apply) Nucleosides	- 102 you want the followidence of significant drug or with part medical and the significant drug or with part medical significant drug or with part of the significant drug or with part of	Millowing pranted of and day resistance used to be a selected freshment of all treatments drug resistance where all treatments drug resistance. We real treatments drug resistance for the selected freshments and treatments drug resistance for the selected freshment of the select	wing to contensive in your reply a your reply recommend an untal of absorption a commend an untal of absorption and drug Industry I Sequency I Sequency I Amprenaver	mind course of treatment and drug metabolum Computer of treatment Listues metabolum Consider a results. Bulbutters	Leaves to consider in sider a regimen contact to consider in chooses gamen containing nuclear to the contact of	g a regiment
No. 1 Comments No. 1 Chair Chair No. 1 Cha	Regiment - Check at see not show genetype o command towardy patents o proteam substance complaint of the control towards of the control t	- 102 you want the followdence of significant drug to with part medical significant drug to with part medical for should be supplied to the significant drug to with part medical for should be supplied to the significant drug to with part medical for should be supplied to the significant drug t	Mount (1960) Mo	A vous reply We recommend an utual or absorption and drug From I Indianary I Amprenava From I Indianary	mind course of freatment and drug metabolism Gon	Traver to consider in order a regimen contact to consider in choosing gamen containing nucleus of Force of Forc	and regiment cost of a regiment
NEAR TEACH TO THE TEACH TO THE TEACH TO THE STATE THE ST	Regiment - Check at great the complaints of the	- 102 You want the followidence of significant drug or with part medical part of significant drug or with significant drug or with part of significant drug or with s	Mount of the control	a vous reply a vous reply b We recommend an initial ce g absorption and drug Indiany Indiany I Indiany I Amprenave Amprenave Pro	maked course of freshment and drug metabolum Consider a remark Listuage Consideration Consider	Issues to consider in sider a regimen contact to consider in choosing to consider in choosing much segmen containing nuclear in the contact i	and regiment cost of a regiment
No. 1 Second Regimen State of Page 1 Second Regimen	Primas 711 711 711 712 712 713 714 715 715 716 717 717 717 717 717	- 102 You want the followidence of significant drug or with part medical part of significant drug or with significant drug or with part of significant drug or with s	Modes Mo	vius reply read as a second as	mind course of treatment and drug metabolum Commetabolum Consider a result in the consideration of the consideratio	Leaves to consider in eider a regimen contact to consider in choosing to consider in choosing in English to consider in contact in English to consider in English to contact in	and regiment cost of a regiment
Wenythens, Moret NEEL TNALT 244 F The scalete de regemen include per nucleosedes and a F Thu scalete a protense inhabite First Regimen I Table I ddl Comments First Regimen I Table I ddl I ddd I dde I dde	By Regiment Check at the spot of the complant	- 102 You want the followidence of significant drug or with part medical part of significant drug or with significant drug or with part of significant drug or with s	Mount of the control	vius reply read as a second as	maked course of freshment and drug metabolum Consider a remark Listuage Consideration Consider	Essues to consider in elder a regimen contain to consider in choose to constaining nucleus of Foscarins [F]	and regiment cost of a regiment
No. 1	By Regiment Check at the spot of the complant	- 102 You want the followidence of significant drug or with part medical part of significant drug or with significant drug or with part of significant drug or with s	Mount of the control	vius reply read as a second as	maked course of freshment and drug metabolum Consider a remark Listuage Consideration Consider	Leaves to consider in eider a regimen contact to consider in choosing to consider in choosing in English to consider in contact in English to consider in English to contact in	and regiment cost of a regiment
Newstance Motor Nutri FRAIT 243 F This stolate do regamen include pet mucheomides and a F This stolate do regamen include pet mucheomides and a protense inshibite First Regimen T ZDV I ddl I ddl I ddl Comments Second Regime F ZDV I ddl Comments Comments	We cause 1 71 I 71 I 71 I 71 V W Regiment Check it the ser not thow genetypes o terminal towardy patients octombal towardy patients over genetypes over genetypes over genetypes over compliant over genetypes over compliant Check all that apply) Nucleosides Nucleosides Nucleosides 1 ' 94 V T abas over	- 102 You want the followidence of significant drug or with part medical part of significant drug or with significant drug or with part of significant drug or with s	Mount of the control	Viga to Jamessaci	metal course of treatment and drug metabolism. Consider a remarks a faithful consider a remarks	Estuss to consider in elder a regimen contact to consider in choosing much contact to consider in choosing much contact to consider in contact to consider in contact to consider in contact to consider in contact to conta	nor—
No. 1	We cause 1 71 I 71 I 71 I 71 V 9 Regiment Check at the serious obtained towards patients towards patients obtained towards patients over genotypus evidents over genotypus evidents over genotypus evidents over genotypus evidents. Nucleosides Nucleosides Nucleosides Nucleosides 1 ' 97 C Tabasawa In (check all that apply) Nucleosides Nucleosides Nucleosides On (check all that apply) Nucleosides On (check all that apply) Nucleosides On (check all that apply)	Prices 2002 - 102 you want the followdence of significant drug to with part medic to wi	Linving printed of an indeed printed p	A YOUR FORD AS A SALES AND AS A SALES AS A S	mind course of freatment and drug metabolum Consider an oburse of treatment I I I I I I I I I I I I I I I I I I I	Leaves to consider in elder a regimen containing nucleon of the consider in choose gamen containing nucleon of the contain	age a regional and consider and
Number of State of St	Regiment Check at that apply) Recheck all that apply) Nucleosides In check all that apply) Nucleosides In check all that apply) Nucleosides	Firema Bush - 102 you want the followdence of signature	Model Medical Property of the Control of the Contro	Viga to Jamessael a vous reply Brown I Sagurnavr I Sagurnavr I Amprenavr I Sagurnavr I Amprenavr I Sagurnavr I Amprenavr I Sagurnavr I Sagurnavr I Amprenavr I Sagurnavr I Sagurnavr	manal course of freatment and drug metabolism Consider a remetabolism Consideration Cons	Essues to consider in ender a regimen containing nucleon of the consider in choose gamen containing nucleon of the contain	age a regional and consider and
No. 1	We cause 1 71 I 71 I 71 I 71 V 9 Regiment Check at the serious obtained towards patients towards patients obtained towards patients over genotypus evidents over genotypus evidents over genotypus evidents over genotypus evidents. Nucleosides Nucleosides Nucleosides Nucleosides 1 ' 97 C Tabasawa In (check all that apply) Nucleosides Nucleosides Nucleosides On (check all that apply) Nucleosides On (check all that apply) Nucleosides On (check all that apply)	Firema Bush - 102 you want the followdence of signature	Illowing practed or and story research in moduli feature in moduli	A YOUR FORD AS A SALES AND AS A SALES AS A S	manal course of freatment and drug metabolism Consider a remetabolism Consideration Cons	Leaves to consider in elder a regimen containing nucleon of the consider in choose gamen containing nucleon of the contain	age a regional and consider and
Newtons Motor Nutri FRAIT 200 F Nutri FRAIT 200 F Nutri FRAIT Nut	We cause 1 71 I 71 I 71 I 71 V 9 Regiment Check at the serious obtained towards patients towards patients obtained towards patients over genotypus evidents over genotypus evidents over genotypus evidents over genotypus evidents. Nucleosides Nucleosides Nucleosides Nucleosides 1 ' 97 C Tabasawa In (check all that apply) Nucleosides Nucleosides Nucleosides On (check all that apply) Nucleosides On (check all that apply) Nucleosides On (check all that apply)	Firema Bush - 102 you want the followdence of signature	Illowing practed or and story research in moduli feature in moduli	A YOUR FORD AS A SALES AND AS A SALES AS A S	manal course of freatment and drug metabolism Consider a remetabolism Consideration Cons	Essues to consider in ender a regimen containing nucleon a regimen containing nucleon a regimen containing nucleon and the endership of the end o	MMP.
New Comments North Fisher No	We check all that apply) Nucleosides 'depty 'depty	Firema Bush - 102 you want the followdence of signature	Illowing practed or and story research in moduli feature in moduli	A YOUR FORD AS A SALES AND AS A SALES AS A S	manal course of freatment and drug metabolism Consider a remetabolism Consideration Cons	Essues to consider in older a regimen contain to consider in choose against containing and to consider in the containing and th	MMP.
Newtons Motor Nutri FRAIT 200 F Nutri FRAIT 200 F Nutri FRAIT Nut	We check all that apply) Nucleosides 'depty 'depty	Firema Bush - 102 you want the followdence of signature	Illowing practed or and story research in moduli feature in moduli	A YOUR FORD AS A SALES AND AS A SALES AS A S	manal course of freatment and drug metabolism Consider a remetabolism Consideration Cons	Essues to consider in older a regimen contain to consider in choose against containing and to consider in the containing and th	ner

FIG. 18.